Kobayashi Pharmaceutical Co Stock Five Year Return
KBYPFDelisted Stock | USD 32.49 0.00 0.00% |
Kobayashi Pharmaceutical Co fundamentals help investors to digest information that contributes to Kobayashi Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Kobayashi Pink Sheet. The fundamental analysis module provides a way to measure Kobayashi Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kobayashi Pharmaceutical pink sheet.
Kobayashi |
Kobayashi Pharmaceutical Co Company Five Year Return Analysis
Kobayashi Pharmaceutical's Five Year Return is considered one of the best measures to evaluate fund performance, especially from the mid and long term perspective. It shows the total annualized return generated from holding equity for the last five years and represents capital appreciation of the investment, including all dividends, losses, and capital gains distributions.
More About Five Year Return | All Equity Analysis
Five Year Return | = | (Mean of Monthly Returns - 1) | X | 100% |
Although Five Year Returns can give a sense of overall investment potential, it is recommended to compare equity performance with similar assets for the same five year time interval. Similarly, comparing overall investment performance over the last five years with the appropriate market index is a great way to determine how this equity instrument will perform during unforeseen market fluctuations.
CompetitionAccording to the company disclosure, Kobayashi Pharmaceutical Co has a Five Year Return of 0.0%. This indicator is about the same for the Consumer Defensive average (which is currently at 0.0) sector and about the same as Household & Personal Products (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Kobayashi Five Year Return Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kobayashi Pharmaceutical's direct or indirect competition against its Five Year Return to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Kobayashi Pharmaceutical could also be used in its relative valuation, which is a method of valuing Kobayashi Pharmaceutical by comparing valuation metrics of similar companies.Kobayashi Pharmaceutical is currently under evaluation in five year return category among its peers.
Kobayashi Fundamentals
Return On Equity | 0.0968 | |||
Return On Asset | 0.0633 | |||
Profit Margin | 0.12 % | |||
Operating Margin | 0.16 % | |||
Current Valuation | 3.94 B | |||
Shares Outstanding | 76.01 M | |||
Shares Owned By Insiders | 34.50 % | |||
Shares Owned By Institutions | 21.77 % | |||
Price To Earning | 34.29 X | |||
Price To Book | 2.85 X | |||
Price To Sales | 0.03 X | |||
Revenue | 155.25 B | |||
Gross Profit | 88.77 B | |||
EBITDA | 32.49 B | |||
Net Income | 19.71 B | |||
Cash And Equivalents | 116.15 B | |||
Total Debt | 596 M | |||
Debt To Equity | 0 % | |||
Current Ratio | 3.92 X | |||
Book Value Per Share | 2,653 X | |||
Cash Flow From Operations | 22.42 B | |||
Earnings Per Share | 1.94 X | |||
Number Of Employees | 3.45 K | |||
Beta | 0.27 | |||
Market Capitalization | 5.37 B | |||
Total Asset | 252.55 B | |||
Z Score | 5.4 | |||
Annual Yield | 0.01 % | |||
Net Asset | 252.55 B | |||
Last Dividend Paid | 84.0 |
About Kobayashi Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kobayashi Pharmaceutical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kobayashi Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kobayashi Pharmaceutical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Other Consideration for investing in Kobayashi Pink Sheet
If you are still planning to invest in Kobayashi Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kobayashi Pharmaceutical's history and understand the potential risks before investing.
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |